TOKYO, March 7, 2017 /CNW/ --
- Important Milestone for Growing Taiho's Global Pharmaceutical Operations -
Taiho Pharmaceutical Co., Ltd. of Tokyo announced on March 7, 2017, that it has established its subsidiary Taiho Pharma Canada, Inc. in Oakville, Ontario. The Canadian operations will be managed by Taiho Oncology, Inc., the U.S. R&D and commercial operations of the Taiho Group, based in Princeton, N.J.
The establishment of Taiho Pharma Canada was motivated by the recent successful NDA approval and commercial launch of Lonsurf (R) (IND code: TAS-102, nonproprietary names: trifluridine and tipiracil hydrochloride), Taiho's first cancer product in the U.S. Taiho Pharma Canada will prepare for an NDA submission and for potential commercialization of the product in Canada.
"We are delighted to establish our permanent presence in Canada," said Ross Glover, VP and General Manager of Taiho Pharma Canada. "We believe Taiho Pharma Canada has a great deal to contribute to the health and well-being of Canadians and we look forward to building a strong presence in Canada."
Glover has a proven track record as a successful commercial executive with experience in building and providing strong strategic leadership to specialty products business units, including oncology. Prior to joining Taiho Pharma Canada, Glover led commercial organizations in large and medium-sized bio-pharma companies in Canada, including Sanofi Genzyme, UCB Canada and Abraxis Bioscience. His extensive experience will be an asset to meeting the challenges of establishing Taiho Pharma Canada and managing the NDS process for Lonsurf.
The establishment of Taiho Pharma Canada represents another step towards the globalization of the Taiho Group and providing cancer patients throughout the world with new and innovative chemotherapies for treatment of a wide range of tumor types.
Taiho Pharma Canada, Inc. Overview
- Company Name: Taiho Pharma Canada, Inc.
- Established: December 13, 2016
- Vice President and General Manager: Ross Glover
- Head Office Address:
Taiho Pharma Canada, Inc.
2010 Winston Park Drive, Suite 200
Oakville, Ontario L6H 5R7
- Business: Pharmaceutical Development and Commercialization
About Taiho Pharmaceutical Co., Ltd. (Japan)
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology. Its corporate philosophy takes the form of a pledge: "We strive to improve human health and contribute to a society enriched by smiles." In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer. In areas other than oncology as well, the company creates quality products that effectively treat medical conditions. Always putting customers first, Taiho Pharmaceutical also aims to offer over-the-counter medicinal products that support people's efforts to lead fulfilling and rewarding lives.
For more information about Taiho Pharmaceutical, please visit:
About Taiho Oncology, Inc. (U.S.)
Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has established world-class clinical development and commercial organizations that work urgently to develop and market innovative cancer treatments in the U.S. Taiho Oncology Inc. has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state-of-the-art facilities are helping us to define the way the world treats cancer. It's our work; it's our passion; it's our legacy.
For more information about Taiho Oncology, Inc. please visit:
SOURCE Taiho Pharmaceutical Co., Ltd.
For further information: Yukie Shibata, Public Relations, Taiho Pharmaceutical Co., Ltd., Tel: +81-3-3293-2878, Email: [email protected], http://www.taiho.co.jp/english